CN116999460A - 一种缓解视疲劳的营养素配方及其效果测试方法 - Google Patents
一种缓解视疲劳的营养素配方及其效果测试方法 Download PDFInfo
- Publication number
- CN116999460A CN116999460A CN202310795177.4A CN202310795177A CN116999460A CN 116999460 A CN116999460 A CN 116999460A CN 202310795177 A CN202310795177 A CN 202310795177A CN 116999460 A CN116999460 A CN 116999460A
- Authority
- CN
- China
- Prior art keywords
- nutrient
- test
- formula
- zinc
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 29
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 22
- 230000000694 effects Effects 0.000 title claims abstract description 17
- 238000010998 test method Methods 0.000 title claims abstract description 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 32
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims abstract description 16
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims abstract description 16
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 16
- 235000012680 lutein Nutrition 0.000 claims abstract description 16
- 229960005375 lutein Drugs 0.000 claims abstract description 16
- 239000001656 lutein Substances 0.000 claims abstract description 16
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 16
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 16
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 16
- 235000010930 zeaxanthin Nutrition 0.000 claims abstract description 16
- 239000001775 zeaxanthin Substances 0.000 claims abstract description 16
- 229940043269 zeaxanthin Drugs 0.000 claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- 230000004438 eyesight Effects 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 6
- 235000016804 zinc Nutrition 0.000 claims abstract description 6
- 239000000969 carrier Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims description 38
- 208000024891 symptom Diseases 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 5
- 239000000902 placebo Substances 0.000 claims description 4
- 229940068196 placebo Drugs 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 206010015958 Eye pain Diseases 0.000 claims description 3
- 206010034960 Photophobia Diseases 0.000 claims description 3
- 206010047513 Vision blurred Diseases 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 206010000060 Abdominal distension Diseases 0.000 claims description 2
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 208000024330 bloating Diseases 0.000 claims description 2
- 229940038879 chelated zinc Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 229940071566 zinc glycinate Drugs 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract description 10
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- 239000000049 pigment Substances 0.000 abstract description 6
- 208000002177 Cataract Diseases 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 201000008525 senile cataract Diseases 0.000 abstract description 2
- 208000002780 macular degeneration Diseases 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种缓解视疲劳的营养素配方及其效果测试方法,该配方每100克中含有的原材料按重量记包括活性成分与载体;所述活性成分包括:玉米黄素:0.15~7.5克;叶黄素:0.15~7.5克;所述配方中除活性成分之外的余量为载体;玉米黄素和叶黄素不仅是黄斑色素也具有抗氧化作用,与维生素C、维生素E、锌等人体重要的抗氧化剂共同作用,对人体抗氧化具有非常重要的作用;叶黄素和玉米黄素特异性吸收蓝光的特性,有益于保护皮肤免受蓝光伤害;应用本发明配方所制备的营养素具有抗氧化、缓解眼疲劳、保护视力、对老年性黄斑变性和白内障具有预防和减缓进程的作用。
Description
技术领域
本发明涉及营养素技术领域,具体是一种缓解视疲劳的营养素配方及其效果测试方法。
背景技术
人体眼睛结构非常复杂,但与人体其他组织不同,眼睛的组织自从形成后就不更新,比如人体晶状体中的大部分细胞是在胚胎时形成的,形成后在人的一生中都不更新,因此视力会随着年龄增长而衰退。
当光沿着瞳孔穿过角膜、房水后由晶状体聚焦,聚焦的光线穿过玻璃体落在视网膜上,视网膜上的细胞将光能量转化为神经冲动通过视神经传递给大脑而形成影像。晶状体的蛋白质可能被氧化而损伤,随着年龄增长而累积的损伤导致穿透性降低,最终会形成白内障可能引起失明。组成视网膜是视神经组织的细胞也同样不能有丝分裂,这些细胞一旦损伤是永久性损伤,会引起视网膜退化,进而引起代谢残片堆积,最终随着年龄增长导致视力下降甚至失明。这种随年龄增长晶状体、视网膜的衰退恶化最终失明被称为老年性黄斑变性(AMD)。目前对于AMD还没有有效的治疗手段,只能设法预防和减缓AMD发展。研究表明活性氧是导致AMD的发病主要因素,结果表明AMD患者血液中抗氧化能力明显低于正常对照人群组,因此得出结论氧化有可能是AMD的致病因素。补充维生素C、维生素E等抗氧化剂可延缓AMD的发展进程。
当不同波长的光进入眼睛时首先经过角膜和晶状体的过滤,角膜可以扫描所有紫外光,而晶状体反射阻止紫外线进入眼睛,经过晶状体过滤掉紫外线的光线最终会到达视网膜。角膜和晶状体的紫外扫描功能可能会损耗眼睛的构造,光落在视网膜上会损伤一些细胞,可见光中的蓝波长刺激视网膜细胞形成自由基的能力比红波长要强100倍,因此蓝光是损伤视网膜的主要元凶。黄斑是视网膜中聚集光接收器、负责视敏度的核心区域,黄斑中含有丰富的叶黄素和玉米黄素,二者构成了黄斑色素。黄斑色素具有抗氧化作用,预防高氧含量引起的自由基对光接收细胞的损伤;玉米黄素和叶黄素过滤蓝光,以免蓝光到达黄斑,可显著减轻视网膜氧压力。人体无法自身合成叶黄素和玉米黄素的,必须通过饮食获得,如果摄入叶黄素和玉米黄素不足可引起眼睛的各种不适,甚至导致白内障和黄斑变性。
因此,针对上述问题提出一种缓解视疲劳的营养素配方及其效果测试方法。
发明内容
为了弥补现有技术的不足,解决上述至少一个问题,本发明提出的一种缓解视疲劳的营养素配方及其效果测试方法。
一种缓解视疲劳的营养素配方,该配方每100克中含有的原材料按重量记包括活性成分与载体;
所述活性成分包括:
玉米黄素:0.15~7.5克;
叶黄素:0.15~7.5克;
维生素C:1~30克;
维生素E:0.1~15克;
维生素A:0.02~0.4克;
锌:0.15~10克;
所述配方中除活性成分之外的余量为载体。
优选的,所述锌包括葡萄糖酸锌、柠檬酸锌、甘氨酸锌、乳酸锌、氨基酸螯合锌中的一种或多种组合。
优选的,所述载体为食品、药物学上可接受的载体,不同载体与活性成分组合,对应制备成不同的剂型,包括散剂、丸剂、胶囊剂、片剂、微囊剂、软胶囊剂、栓剂、膏剂、酊剂、冲剂中的一种。
一种缓解视疲劳的营养素配方的效果测试方法,适用于权利要求1-3任一一种缓解视疲劳的营养素配方,该效果测试方法包括以下步骤:
S1:按照配方以一种活性成分计量制备营养素胶囊;
S2:以整数受试者采取双盲方进行药性测试,分为试食组与对照组;
S3:观察受试者试验开始与试验结束时各项功能性指标情况,按照症状轻重统计;
S4:针对统计数据进行处理和结果判定;
S5:以不同S1配方中活性成分计量制备营养素胶囊,重复S2-S4。
优选的,所述S2中,试食组食用营养素胶囊,对照组食用安慰剂;受试者年龄、性别、视力因素具有可比性,采用自身前后对照和组件对照分组。
优选的,所述S3中,功能性指标包括:病史、眼部自觉症状;其中眼部自觉症状包括:眼胀、眼痛、畏光、视物模糊、眼干涩;按照症状轻重统计,其中,重症3分、中度2分、轻症1分。
本发明的有益之处在于:
本发明配方中的活性成分包括玉米黄素和叶黄素、抗氧化剂和维生素A;本配方不仅用于眼部保健还有益于人体皮肤健康;玉米黄素和叶黄素不仅是黄斑色素也具有抗氧化作用,与维生素C、维生素E、锌等人体重要的抗氧化剂共同作用,对人体抗氧化具有非常重要的作用;叶黄素和玉米黄素特异性吸收蓝光的特性,有益于保护皮肤免受蓝光伤害;应用本发明配方所制备的营养素具有抗氧化、缓解眼疲劳、保护视力、对老年性黄斑变性和白内障具有预防和减缓进程的作用。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,还可以根据这些附图获得其它的附图。
图1为本发明中营养素配方的效果测试方法流程图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
实施例1
按照本配方比例,每100克营养素中含有:玉米黄素:3克;叶黄素3克,维生素C:30克,维生素E:15克,维生素A:0.04克,葡萄糖酸锌:30克,大豆油33.96克。
制备成软胶囊,胶囊每粒0.56克,每日服用1粒。
1.胶囊效果试验方法,如附图1所示;
1.1试验分组:以40例受试者采用随机双盲法分为试食组和安慰剂对照组,每组各20人,年龄35~65岁。
试食组男12人,女8人,年龄46.3±15.1岁;
对照组男10人,女10人,年龄48.2±16.3岁。
年龄、性别、视力等因素具有可比性,试验采用自身前后对照和组间对照。
1.2试食方法
试食组服用本发明实施例1所制备的软胶囊,对照组服用安慰剂,均为每日1次,每次1粒,服用时间为30天。
1.3观察指标
各项指标于试食试验开始及结束时各测定1次。
功效性指标:详细询问病史,眼部自觉症状:眼胀、眼痛、畏光、视物模糊、眼干涩等。
按症状轻重(重症3分、中度2分、轻症1分)在试食前后统计积分值,并就其主要症状改善情况(每一症状改善1分为有效,改善2分为显效),计算症状改善率。
眼科常规检查:外眼、眼底。
明视持久度测定:明视时间对注视时间的百分比称为明视持久度,测定时间为3min,测定2次取平均值。
远视力检查:使用国际视力表进行检查。
1.4数据处理和结果判定
数据处理用统计软件stata6.0计算分析数据。
自身对照资料采用配对t检验,两组均数比较采用成组t检验,后者需要进行方差齐性检验,对非正态分布或方差不齐分析数据进行适当的变量转换,待满足正态方差齐性后,用转换的数据进行t检验;若转换数据仍不能满足正态方差齐性要求,改用t’检验或秩和检验;对变异系数太大,如CV>50%的资料,应用秩和检验。功效指标采用X2检验判定P值。
结果:
表一试食前后明视持久度变化的比较(X±s,%)
组别 | 例数 | 试食前 | 试食后 | 提高率 |
试食组 | 20 | 55.32±8.12 | 73.28±10.03 | 17.96 |
对照组 | 20 | 58.63±10.07 | 59.93±10.59 | 1.30 |
注:试食前后自身对照P<0.01;组间对照P<0.01
表二试食前后两组远视力变化的比较(X±s,%)7
注:试食前后自身比较P<0.05;组间对照P<0.05
表三症状积分统计(X±s,%)
组别 | 例数 | 试食前 | 试食后 |
试食组 | 20 | 7.18±2.09 | 4.08±2.12 |
对照组 | 20 | 7.15±1.93 | 5.96±2.31 |
注:试食前后自身比较P<0.01;组间对照P<0.05
从以上结果可以看到试食本发明的营养配方后,试食组自身比较或试食组与对照组组间比较,症状改善有效率或症状总积分差异均有显著性(p<0.05);明视持久度差异有显著性(p<0.05),且平均明视持久度提高大于等于10%。同时视力改善率不明显降低,因此可判定本发明配方具有有助于缓解视疲劳功能的作用。
实施例2
按照本配方比例,每100克营养素中含有:每100克含:玉米黄素:7.5克;叶黄素:7.5克,维生素C:10克,维生素E:5克,维生素A:0.4克,柠檬酸锌:60克,大豆油9.6克。制备成软胶囊,胶囊每粒0.5克,每日服用1粒。
结果:
营养素缓解视疲劳的检测结果与实施例1相同。
一种缓解视疲劳的营养素配方,包括
作为本发明的一种实施方式,所述;
黄斑区中心的唯一色素玉米黄素以及遍布视网膜的叶黄素,两种眼组织中最重要的色素同时补充是目前唯一能有效控制和预防黄斑变性的手段;同时辅以抗氧化剂及维生素A,消除自由基对眼组织的伤害,对消除眼疲劳、保护视力有积极的作用。
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。
Claims (6)
1.一种缓解视疲劳的营养素配方,其特征在于:该配方每100克中含有的原材料按重量记包括活性成分与载体;
所述活性成分包括:
玉米黄素:0.15~7.5克;
叶黄素:0.15~7.5克;
维生素C:1~30克;
维生素E:0.1~15克;
维生素A:0.02~0.4克;
锌:0.15~10克;
所述配方中除活性成分之外的余量为载体。
2.根据权利要求1所述的一种缓解视疲劳的营养素配方,其特征在于:所述锌包括葡萄糖酸锌、柠檬酸锌、甘氨酸锌、乳酸锌、氨基酸螯合锌中的一种或多种组合。
3.根据权利要求2所述的一种缓解视疲劳的营养素配方,其特征在于:所述载体为食品、药物学上可接受的载体,不同载体与活性成分组合,对应制备成不同的剂型,包括散剂、丸剂、胶囊剂、片剂、微囊剂、软胶囊剂、栓剂、膏剂、酊剂、冲剂中的一种。
4.一种缓解视疲劳的营养素配方的效果测试方法,适用于权利要求1-3任一一种缓解视疲劳的营养素配方,其特征在于:该效果测试方法包括以下步骤:
S1:按照配方以一种活性成分计量制备营养素胶囊;
S2:以整数受试者采取双盲方进行药性测试,分为试食组与对照组;
S3:观察受试者试验开始与试验结束时各项功能性指标情况,按照症状轻重统计;
S4:针对统计数据进行处理和结果判定;
S5:以不同S1配方中活性成分计量制备营养素胶囊,重复S2-S4。
5.根据权利要求4所述的一种缓解视疲劳的营养素配方的效果测试方法,其特征在于:所述S2中,试食组食用营养素胶囊,对照组食用安慰剂;受试者年龄、性别、视力因素具有可比性,采用自身前后对照和组件对照分组。
6.根据权利要求5所述的一种缓解视疲劳的营养素配方的效果测试方法,其特征在于:所述S3中,功能性指标包括:病史、眼部自觉症状;其中眼部自觉症状包括:眼胀、眼痛、畏光、视物模糊、眼干涩;按照症状轻重统计,其中,重症3分、中度2分、轻症1分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310795177.4A CN116999460A (zh) | 2023-06-29 | 2023-06-29 | 一种缓解视疲劳的营养素配方及其效果测试方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310795177.4A CN116999460A (zh) | 2023-06-29 | 2023-06-29 | 一种缓解视疲劳的营养素配方及其效果测试方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116999460A true CN116999460A (zh) | 2023-11-07 |
Family
ID=88568156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310795177.4A Pending CN116999460A (zh) | 2023-06-29 | 2023-06-29 | 一种缓解视疲劳的营养素配方及其效果测试方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116999460A (zh) |
-
2023
- 2023-06-29 CN CN202310795177.4A patent/CN116999460A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ozawa et al. | Bilberry extract supplementation for preventing eye fatigue in video display terminal workers | |
US9889173B2 (en) | Composition for improving macular pigment density and preventing or treating age-related macular degeneration | |
CN101595977B (zh) | 有益于眼睛明视持久度的配方食品及其应用 | |
CN102763847B (zh) | 一种具有缓解视疲劳的保健食品及其制备方法 | |
CN101199526A (zh) | 明目护视保健制剂及其制备方法 | |
CN104435763B (zh) | 一种治疗眼病的药物 | |
CN101856118A (zh) | 一种缓解视疲劳的保健食品及其制备方法 | |
CN103798808A (zh) | 一种营养素配方及在缓解视疲劳的食品或药物中的应用 | |
US9226940B2 (en) | Method of treating ocular disorders | |
CN101416741A (zh) | 一种用于缓解视疲劳的保健食品 | |
Koçak Altintas et al. | Bilateral keratoconus associated with Hashimoto's disease, alopecia areata and atopic keratoconjunctivitis | |
CN113826894A (zh) | 一种缓解视疲劳胶囊及其制备方法 | |
CN105520137A (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
CN108324705A (zh) | 含茶氨酸、γ-氨基丁酸和花青素的缓解视疲劳的组合物 | |
CN116999460A (zh) | 一种缓解视疲劳的营养素配方及其效果测试方法 | |
CN101040893A (zh) | 越橘护视胶囊及其制备方法 | |
CN112385755A (zh) | 一种具有视力保健作用的果蔬饮品的制造工艺 | |
JP2020025503A (ja) | 眼の老化予防剤および眼の老化予防用サプリメント | |
Saving | Age Related Macular Degeneration | |
AU2020352751B2 (en) | Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters | |
Mehkri et al. | The effects of lutein and zeaxanthin (Lute-gen®) supplementation, with and without natural mixed carotenoids on macular pigment optical density in healthy adult subjects: A randomized, double-blind, placebo-controlled study | |
Synek et al. | Epidemiology and quality of life of patients with age-related macular degeneration | |
CN117547550A (zh) | 一种预防和治疗白内障的药物及其制备方法 | |
Steinmetz et al. | Suspected macular degeneration in a captive Western lowland gorilla (Gorilla gorilla gorilla) | |
Vachhani et al. | Chakshushya Basti and Adjuvant Ayurvedic Remedies in the Management of Keratoconus–A Case Report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |